Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2011 - 2026)
Travere Therapeutics (TVTX) posted Net Income towards Common Stockholders of -$500000.0 for Q1 2026, down 102.02% on a QoQ basis from $24.7 million in Q4 2025.
Travere Therapeutics (TVTX) Net Income towards Common Stockholders (2011 - 2026) Analysis & Trends
Travere Therapeutics' Net Income towards Common Stockholders history runs 16 years deep, the most recent figure standing at -$500000.0 for Q1 2026.
- Quarterly Net Income towards Common Stockholders changed N/A year-over-year to -$500000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.2 million (up 3013.96% YoY) and the FY2025 annual result came in at $24.7 million, up 2801.09% from the prior year.
- Net Income towards Common Stockholders was -$500000.0 for Q1 2026 at Travere Therapeutics, down from $24.7 million in the prior quarter.
- Across five years, Net Income towards Common Stockholders topped out at $240.0 million in Q3 2023 and bottomed at -$1.6 million in Q4 2023.
- A 5-year average of $24.4 million and a median of $8.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2023 — Net Income towards Common Stockholders tumbled 107.96% — and 2025, when it soared 164866.67%.
- Travere Therapeutics' Net Income towards Common Stockholders stood at $19.8 million in 2022, then slumped by 107.96% to -$1.6 million in 2023, then soared by 99.05% to -$15000.0 in 2024, then surged by 164866.67% to $24.7 million in 2025, then sank by 102.02% to -$500000.0 in 2026.
- Business Quant data shows TVTX's Net Income towards Common Stockholders at -$500000.0 in Q1 2026, $24.7 million in Q4 2025, and -$15000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -625.73 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -14.46 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 227.36 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -0.68 |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 366.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Travere Therapeutics | 5.25 Bn | 5.25 Bn | 125.25 Mn | -500,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -500,000.00 |
| Dec 31, 2025 | 24.72 Mn |
| Dec 31, 2024 | -15,000.00 |
| Sep 30, 2024 | -59,000.00 |
| Jun 30, 2024 | -757,000.00 |
| Mar 31, 2024 | -103,000.00 |
| Dec 31, 2023 | -1.58 Mn |
| Sep 30, 2023 | 239.98 Mn |
| Jun 30, 2023 | 16.30 Mn |
| Mar 31, 2023 | 10.23 Mn |
| Dec 31, 2022 | 19.81 Mn |
| Sep 30, 2022 | 14.41 Mn |
| Jun 30, 2022 | 12.99 Mn |
| Mar 31, 2022 | 5.78 Mn |
| Dec 31, 2021 | -88.77 Mn |
| Sep 30, 2021 | -35.64 Mn |
| Jun 30, 2021 | -39.01 Mn |
| Mar 31, 2021 | -53.87 Mn |
| Dec 31, 2020 | -121.62 Mn |
| Sep 30, 2020 | -22.55 Mn |